Keeping an Eye on EyePoint Pharmaceuticals Inc. (EYPT) After Insider Trading Activity


EyePoint Pharmaceuticals Inc.’s filing revealed that its 10% Owner EW Healthcare Partners, L.P. unloaded Company’s shares for reported $0.93 million on Aug 25. In the deal valued at $11.00 per share,84,656 shares were sold. As a result of this transaction, EW Healthcare Partners, L.P. now holds 3,799,104 shares worth roughly $ 44.26 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, EW Healthcare Partners, L.P. sold 139,280 shares, generating $2,036,093 in total proceeds. Upon selling the shares at $14.62, the 10% Owner now owns 3,883,760 shares.

Before that, EW Healthcare Partners, L.P. sold 121,103 shares. EyePoint Pharmaceuticals Inc. shares valued at $1,580,915 were divested by the 10% Owner at a price of $13.05 per share. As a result of the transaction, EW Healthcare Partners, L.P. now holds 4,023,040 shares, worth roughly $46.87 million.

Robert W. Baird initiated its EyePoint Pharmaceuticals Inc. [EYPT] rating to an Outperform in a research note published on Monday, April 21, 2023; the price target was $33. PT values the company’s stock at a premium of 64.7 to its Monday closing price.

Price Performance Review of EYPT

On Monday, EyePoint Pharmaceuticals Inc. [NASDAQ:EYPT] saw its stock jump 3.01% to $11.65. On the same session, the stock had its day’s lowest price of $11.2632, but rose to a high of $12.075. Over the last five days, the stock has lost -24.15%. EyePoint Pharmaceuticals Inc. shares have risen nearly 232.86% since the year began. Nevertheless, the stocks have risen 8.37% over the past one year. While a 52-week high of $15.63 was reached on 08/21/23, a 52-week low of $2.19 was recorded on 03/24/23. SMA at 50 days reached $10.84, while 200 days put it at $5.95. A total of 0.5 million shares were traded, compared to the trading of 0.82 million shares in the previous session.

Levels Of Support And Resistance For EYPT Stock

The 24-hour chart illustrates a support level at 11.25, which if violated will result in even more drops to 10.85. On the upside, there is a resistance level at 12.06. A further resistance level may holdings at 12.47. The Relative Strength Index (RSI) on the 14-day chart is 45.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.87, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.08%. Stochastics %K at 25.02% indicates the stock is a holding.

How much short interest is there in EyePoint Pharmaceuticals Inc.?

A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc. stocks on Aug 14, 2023, growing by 0.27 million shares to a total of 5.05 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 4.78 million shares. There was a rise of 5.35%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 23.29% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.45.

EyePoint Pharmaceuticals Inc. [EYPT] – Who Are The Largest Shareholders?

In filings from Franklin Advisers, Inc., it is revealed that the company now owns 5,019,568 shares, or roughly 14.63% of the outstanding EYPT shares. In other words, the investor’s shares have fallen by -712,757 from its previous 13-F filing of 5732325.0. Additionally, Suvretta Capital Management LLC increased 0.85% of its stake after which the total value it holdings stand at $42,798,713. Over the last quarter, Cormorant Asset Management LP purchased 2,974,935 shares of EyePoint Pharmaceuticals Inc., while Adage Capital Management LP bought -167,748 shares. At present, BlackRock Fund Advisors is holding 1,553,753 shares valued at $19.42 million. The Vanguard Group, Inc. owned 1,365,407 shares of the company at the time of its most recent 13F filing, worth $17.07 million.

According to FactSet, EyePoint Pharmaceuticals Inc.’s share price will average $31.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 165.25 percent from its previous closing price of $11.31. Analysts expect EyePoint Pharmaceuticals Inc. stock to reach the higher price of $55.00, while the lowest price estimate is $22.00. However, 8 analysts have rated EYPT stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here